Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

100%

5 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
5(100.0%)
5Total
Phase 3(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT00243646Phase 3Terminated

Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial

Role: lead

NCT00247312Phase 3Completed

Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial

Role: lead

NCT00241384Phase 3Completed

Low Dose Supplemental External Radiation With Pd-103 Versus Pd-103 Alone for Prostate Cancer

Role: lead

NCT00494039Phase 3Unknown

I-125 Versus Pd-103 for Low Risk Prostate Cancer

Role: collaborator

NCT00494546Phase 3Completed

High Versus Low Dose Supplemental External Radiation With Pd-103 for Prostate Cancer

Role: collaborator

All 5 trials loaded